Emergent Biosolutions Inc (EBS)

[mlkrborn]

down 1.33 to $13 'cause:
Shares of vaccine maker PharmAthene Inc. (PIP, $1.69, -$1.57, -48.16%) fell a day after the Department of Health and Human Services changed its approach in requesting anthrax vaccines. HHS canceled a request for proposals on recombinant protective antigen anthrax vaccine because it didn't believe vaccine developers submitting proposals could have product ready for licensure by the Food and Drug Administration within eight years.
Emergent BioSolutions Inc. (EBS, $12.52, -$1.88, -13.06%) also declined on the anthrax vaccine news, though it said the decision has no impact on its $400 million procurement contract with the Centers for Disease Control and Prevention for the delivery of 14.5 million doses of BioThrax--the only vaccine licensed by the FDA for the prevention of anthrax --into the Strategic National Stockpile.